Replimune Group, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Replimune Group, Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-39.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 69% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-69.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 78% of Healthcare companies in United States.
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 56% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Replimune Group, Inc. made a loss over the last year. Replimune Group, Inc. owes $0.58 for every $1 it owns. Replimune Group, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Mar 2026.
P/E ratio
LossReplimune Group, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
10.69The share price is 10.69 times Replimune Group, Inc.'s book value per share, higher than 87% of Healthcare companies in United States.
Market cap
$1.1 BThe total market value of all of Replimune Group, Inc.'s shares at today's price (share price × number of shares), larger than 65% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$106 MWhat Replimune Group, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.12Net worth divided by the number of shares. The share price of $11.99 is 10.7 times this, which is the P/B above.
Return on equity (ROE)
-134.3%Replimune Group, Inc. lost 134.3% of its shareholders' money over the last year, lower than 78% of Healthcare companies in United States.
Owes vs Owns
0.58×Replimune Group, Inc. owes $0.58 for every $1 it owns (moderate), higher than 63% of Healthcare companies in United States.
Dividend yield
NoneReplimune Group, Inc. does not currently pay a dividend.
Profit growth
LossReplimune Group, Inc. made a loss in each of the last two years.
Interest cover
Not coveredReplimune Group, Inc.'s operating profit did not cover its interest costs in the year to Mar 2026.
Cash vs debt
Net cashReplimune Group, Inc. held $157 M more cash than debt (net cash) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Replimune Group, Inc.: $1.1 B ÷ $106 M (30 Jun 2026) = 10.7.
What is Replimune Group, Inc.'s return on equity?
Replimune Group, Inc. lost 134.3% of its shareholders' money over the last year, lower than 78% of Healthcare companies in United States.
How much does Replimune Group, Inc. owe compared with what it owns?
Replimune Group, Inc. owes $0.58 for every $1 it owns (moderate), higher than 63% of Healthcare companies in United States.
Does Replimune Group, Inc. pay a dividend?
No. Replimune Group, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.